Trexquant Investment’s Entrada Therapeutics TRDA Stock Holding History

Trexquant Investment’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03M	Buy	140,143 +57,410	+69%	+$551K	0.01%	1452
2026 Q1	$1.04M	Sell	82,733 -38,547	-32%	-$442K	0.01%	1216
2025 Q4	$1.25M	Sell	121,280 -1,585	-1%	-$13.4K	0.01%	1114
2025 Q3	$713K	Buy	122,865 +112,288	+1,062%	+$657K	0.01%	1243
2025 Q2	$71.1K	Sell	10,577 -566	-5%	-$4.55K	﹤0.01%	1479
2025 Q1	$101K	Buy	+11,143	New	+$139K	﹤0.01%	1499
2024 Q4	–	Sell	-15,681	Closed	-$251K	–	1863
2024 Q3	$251K	Buy	+15,681	New	+$247K	﹤0.01%	1394

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Trexquant Investment's TRDA Position: Q2 2026 in Review

Trexquant Investment increased its Entrada Therapeutics (TRDA) stake by 69% in Q2 2026, buying an estimated $551K and bringing the position to 140,143 shares worth $1.03M. The position accounts for 0.01% of the portfolio, ranked #1452.

Trexquant Investment first reported a position in TRDA in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.25M in Q4 2025. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Trexquant Investment held 140,143 shares of Entrada Therapeutics worth $1.03M as of Q2 2026.
Trexquant Investment bought 57,410 Entrada Therapeutics shares in Q2 2026, an estimated $551K.
Entrada Therapeutics made up 0.01% of Trexquant Investment's portfolio in Q2 2026, its #1452 holding.
Trexquant Investment first reported a position in Entrada Therapeutics in Q3 2024 and has held it in 7 quarters since.
Trexquant Investment's Entrada Therapeutics position peaked at $1.25M in Q4 2025.
128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.